✦ AI AI Company Comparison

Canva vs Recursion Pharmaceuticals — IPO & Funding Comparison

Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.

⚠️
Some data on this page may be outdated. We're verifying.
Data for Canva last verified: Oct 13, 2026. Recursion Pharmaceuticals: verified Oct 17, 2026.

Funding Summary

MetricCanvaRecursion Pharmaceuticals
Total funding$770M$939M
Latest roundSeries FIPO
Amount$200M$436M
DateSep 2021Apr 2021
Valuation$40B$2.4B
Lead investorsT. Rowe PricePublic Markets
Metric Canva Recursion Pharmaceuticals
Valuation$42B$2.5B
Total Funding$770M$939M
IPO StatusPrivatePublic
SectorDesign & CreativeBiotechnology
StagePre-IPOPublic
HeadquartersSydney, AustraliaSalt Lake City, UT
CEOMelanie PerkinsChris Gibson
The IPO Stack Newsletter

Get Tuesday's IPO moves + one deep-dive in your inbox

Scores, valuations, and signals for Canva, Recursion Pharmaceuticals, and 370+ companies. 5-min read every Tuesday.

Canva

Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.

IndustryDesign & Creative
StagePre-IPO
IPO StatusPrivate
Valuation$42B
Total Funding$770M
HeadquartersSydney, Australia

Recursion Pharmaceuticals

AI-powered biotech combining biology, chemistry, and machine learning for drug discovery.

IndustryBiotechnology
StagePublic
IPO StatusPublic
Valuation$2.5B
Total Funding$939M
HeadquartersSalt Lake City, UT

Get the Full Report on Any Company — One-Time $19

Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.

Get All 375+ Reports — $49/mo

Or buy any single company report for $19

Frequently Asked Questions

What is the Canva vs Recursion Pharmaceuticals valuation in 2026? +

Canva is valued at $42B. Recursion Pharmaceuticals is valued at $2.5B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.

How does Canva revenue compare to Recursion Pharmaceuticals? +

Canva reported 4000000000 revenue in 2025. Recursion Pharmaceuticals's revenue is not publicly disclosed. Revenue figures are sourced from TechStackIPO's company database and updated as new data becomes available.

Which is more likely to IPO first — Canva or Recursion Pharmaceuticals? +

Canva filed an S-1 in August 2026 and is actively in the IPO pipeline. Recursion Pharmaceuticals is currently already public. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.

How much has each company raised in total funding? +

Canva has raised $770M. Recursion Pharmaceuticals has raised $939M.

Are Canva and Recursion Pharmaceuticals in the same sector? +

Canva operates in Design & Creative, while Recursion Pharmaceuticals operates in Biotechnology.

What are the key differences between Canva and Recursion Pharmaceuticals as investments? +

Canva is a Design & Creative company valued at $42B with $770M raised. Recursion Pharmaceuticals is a Biotechnology company valued at $2.5B with $939M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.

How can I invest in Canva or Recursion Pharmaceuticals before their IPO? +

Accredited investors can access pre-IPO shares in Canva and Recursion Pharmaceuticals through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.

📡 IPO Intelligence
$49/mo — Unlimited Reports + Real-Time Updates
⚡Unlimited company analysis reports — all 375+ companies
✓Real-time IPO alerts — know the moment S-1s are filed
✓Verified data updated daily — not chatbot hallucinations
💡 Tracking multiple companies? Full access pays for itself after 3 reports.
$49
per month
Subscribe Now →
Cancel anytime · Secure via Stripe
Institutional Research
$19 — Get the Complete canva vs recursion Analysis Brief
✓Executive summary & IPO readiness breakdown
✓Competitive positioning & funding trajectory
✓Bull / bear thesis with pricing projections
✓S-1 timeline estimate & risk assessment
$19
One-time
Don't find it useful? Refund within 7 days.
Secure checkout · Stripe · 24h delivery